Tony Mok
Department of Health(CN)Chinese University of Hong Kong(HK)Chinese University of Hong Kong(CN)Kowloon Hospital(CN)Translational Research in Oncology(FR)Prince of Wales Hospital(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Colorectal Cancer Treatments and Studies, Lung Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma(2009)8,200 cited
- → MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling(2007)4,440 cited
- → First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer(2018)3,394 cited
- → Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer(2013)3,387 cited
- → Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial(2019)3,269 cited
- → Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer(2016)3,266 cited